A Cancer Vaccine Actually Worked. And It Uses the Same Tech as the COVID Shot.

Connie Franciosi is 80 years old. She had melanoma — the kind of skin cancer that kills about 60,000 people a year worldwide. She joined a clinical trial, got an experimental vaccine, and today she is cancer-free.

Her story is one of many coming out of a new study that has oncologists genuinely excited. And that does not happen easily.

Researchers used mRNA technology — the same technology behind some COVID-19 vaccines — to stop melanoma from coming back after surgery. Paired with an immunotherapy drug called Keytruda, the results were striking. Patients who received both showed dramatically lower rates of cancer returning.

The way it works is personal. Scientists take a sample of the patient's tumour, map its unique genetic mutations, then build a vaccine that teaches the immune system to find and destroy exactly those cancer cells. It is not one-size-fits-all. It is made for you specifically.

That is what makes it different from everything before it.

Cancer has always been hard to treat partly because it hides from the immune system. These vaccines hand the body a wanted poster. This is what you are looking for. Go find it.

For Nepal and countries across South Asia where cancer is often diagnosed too late and treatment options are limited, this direction matters. The path from clinical trial to affordable medicine is long — usually a decade or more. But for the first time in a while, this feels like real progress.

Researchers are now testing the same approach on lung, colon and breast cancer. If even half of those trials show similar results, the way we treat cancer will look very different by 2035.